Recently Featured

FDA Places Partial Hold on Biohaven’s Epilepsy Drug Opakalim

September 27, 2026
In a significant regulatory development, the FDA has placed a partial hold on Biohaven’s epilepsy drug, opakalim. This decision comes shortly after Biohaven divested the rights to the therapy, raising questions about the future of the drug’s clinical development. The hold specifically impacts a pivotal study that some analysts consider essential for securing potential approval…

Andy Plump, architect of Takeda’s R&D overhaul, to retire next year

September 27, 2026
Andy Plump, the President of Research and Development at Takeda Pharmaceuticals, is set to retire next year, marking the end of an era for the company. Plump joined Takeda during a turbulent period and has been instrumental in reshaping its R&D strategy, emphasizing collaboration with innovative biotech firms. Under his leadership, Takeda has established a…

AI’s Potential to Transform Rural Health Care Under Examination

September 27, 2026
Recent discussions have highlighted the role of artificial intelligence (AI) in addressing the challenges faced by rural health care systems. As rural hospitals grapple with staffing shortages and limited resources, the integration of AI technologies could streamline operations and enhance patient care. This potential was underscored during recent Senate hearings, where experts like Chris Klomp…

Encoded Secures $275M for Dravet Syndrome Gene Therapy

September 27, 2026
Encoded Therapeutics has successfully raised $275 million to advance its gene therapy candidate targeting Dravet syndrome, a severe form of epilepsy. This significant funding will primarily support a pivotal clinical trial aimed at evaluating the therapy’s efficacy and safety in pediatric patients, a demographic that has been critically underserved in treatment options. The urgency of…

Ongoing Cases